3:I[2885,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],"default"]
4:I[231,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],""]
5:I[9275,[],""]
7:I[1343,[],""]
8:I[8173,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","391","static/chunks/391-cb594d17c6fcd7c7.js","185","static/chunks/app/layout-6784eb5ba9ddff8d.js"],"Image"]
9:I[4019,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","391","static/chunks/391-cb594d17c6fcd7c7.js","185","static/chunks/app/layout-6784eb5ba9ddff8d.js"],"default"]
2:T5ab,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does BOT do?","acceptedAnswer":{"@type":"Answer","text":"Botanix Pharmaceuticals is a dermatology company that develops treatments for skin conditions. Its lead product, Sofdraâ„¢, is an FDA-approved topical gel for treating excessive underarm sweating (primary axillary hyperhidrosis), which it is preparing to launch in the United States."}},{"@type":"Question","name":"Is BOT a good investment?","acceptedAnswer":{"@type":"Answer","text":"Investing in BOT is speculative and carries both high potential rewards and significant risks. The recent FDA approval for Sofdraâ„¢ is a major milestone, but the company's success now hinges on executing a successful commercial launch in the competitive US market. While the potential market is large, investors should consider the significant risks associated with product launches, competition, and future funding requirements."}},{"@type":"Question","name":"What drives BOT's share price?","acceptedAnswer":{"@type":"Answer","text":"BOT's share price is primarily driven by news related to its lead product, Sofdraâ„¢. Key catalysts include updates on the US commercial launch, initial sales figures, securing insurance reimbursement coverage, and manufacturing agreements. Progress in its earlier-stage development pipeline and any capital market activities also significantly influence its valuation."}}]}6:["ticker","BOT","d"]
0:["cABO4PC_c_5qd_aImriE5",[[["",{"children":["asx",{"children":[["ticker","BOT","d"],{"children":["__PAGE__?{\"ticker\":\"BOT\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","BOT","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Botanix Pharmaceuticals Ltd"," (","BOT",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Botanix Pharmaceuticals is a clinical-stage dermatology company focused on developing and commercializing treatments for common skin conditions. Its lead product, Sofdraâ„¢ (sofpironium bromide gel, 12.45%), recently received FDA approval for the treatment of excessive underarm sweating (primary axillary hyperhidrosis). The company leverages its proprietary Permetrexâ„¢ skin delivery technology for its product pipeline, which also includes candidates for rosacea and acne."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$236M"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","$L3",null,{"ticker":"BOT"}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","Botanix Pharmaceuticals has recently transitioned from a development-focused to a commercial-stage company following the landmark FDA approval of its lead asset, Sofdraâ„¢, in June 2024. With a market capitalization of A$227M, the company's current focus is entirely on the successful US commercial launch planned for late 2024. Financially, the company is pre-revenue and has historically been reliant on capital raises to fund its clinical trials and regulatory activities, resulting in a consistent cash burn. Its performance is now less dependent on clinical data and more on its ability to execute a complex and expensive product launch strategy in the competitive US pharmaceutical market.",{"children":"Botanix Pharmaceuticals has recently transitioned from a development-focused to a commercial-stage company following the landmark FDA approval of its lead asset, Sofdraâ„¢, in June 2024. With a market capitalization of A$227M, the company's current focus is entirely on the successful US commercial launch planned for late 2024. Financially, the company is pre-revenue and has historically been reliant on capital raises to fund its clinical trials and regulatory activities, resulting in a consistent cash burn. Its performance is now less dependent on clinical data and more on its ability to execute a complex and expensive product launch strategy in the competitive US pharmaceutical market."}],["$","p","The growth outlook for Botanix is directly tied to the commercial success and market adoption of Sofdraâ„¢. The addressable market for primary axillary hyperhidrosis in the US is significant, estimated to affect over 10 million people, representing a substantial revenue opportunity if a meaningful market share can be captured. Key upcoming catalysts include securing manufacturing and distribution partners, establishing reimbursement with pharmacy benefit managers (PBMs), and reporting initial sales data post-launch. Longer-term growth depends on advancing its earlier-stage pipeline assets for conditions like rosacea, leveraging its Permetrexâ„¢ delivery platform.",{"children":"The growth outlook for Botanix is directly tied to the commercial success and market adoption of Sofdraâ„¢. The addressable market for primary axillary hyperhidrosis in the US is significant, estimated to affect over 10 million people, representing a substantial revenue opportunity if a meaningful market share can be captured. Key upcoming catalysts include securing manufacturing and distribution partners, establishing reimbursement with pharmacy benefit managers (PBMs), and reporting initial sales data post-launch. Longer-term growth depends on advancing its earlier-stage pipeline assets for conditions like rosacea, leveraging its Permetrexâ„¢ delivery platform."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","FDA approval for Sofdraâ„¢ significantly de-risks the asset and provides a clear pathway to near-term revenue generation.",{"children":["â€¢ ","FDA approval for Sofdraâ„¢ significantly de-risks the asset and provides a clear pathway to near-term revenue generation."]}],["$","li","The US market for primary axillary hyperhidrosis is large and underserved, offering substantial 'blue-sky' revenue potential if the commercial launch is successful.",{"children":["â€¢ ","The US market for primary axillary hyperhidrosis is large and underserved, offering substantial 'blue-sky' revenue potential if the commercial launch is successful."]}],["$","li","The proprietary Permetrexâ„¢ drug delivery technology platform provides a foundation for future pipeline development and potential partnership opportunities.",{"children":["â€¢ ","The proprietary Permetrexâ„¢ drug delivery technology platform provides a foundation for future pipeline development and potential partnership opportunities."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Significant commercialization risk exists, including challenges in marketing, sales force effectiveness, and securing favorable reimbursement coverage from insurers.",{"children":["â€¢ ","Significant commercialization risk exists, including challenges in marketing, sales force effectiveness, and securing favorable reimbursement coverage from insurers."]}],["$","li","The company will face competition from established treatments, including high-strength antiperspirants, Botox injections, and other prescription topical medications.",{"children":["â€¢ ","The company will face competition from established treatments, including high-strength antiperspirants, Botox injections, and other prescription topical medications."]}],["$","li","High cash burn is expected to continue or increase to fund the US product launch, likely requiring further capital raises which could dilute existing shareholders.",{"children":["â€¢ ","High cash burn is expected to continue or increase to fund the US product launch, likely requiring further capital raises which could dilute existing shareholders."]}]]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Market Sentiment"}],["$","div",null,{"className":"mt-4 flex items-center gap-3","children":[["$","span",null,{"className":"inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-yellow-500/10 border-yellow-500/30 text-yellow-400","children":["ðŸŸ¡"," ","Mixed"]}],["$","span",null,{"className":"text-xs text-slate-500","children":["Score: ","+","0.02"]}]]}],["$","div",null,{"className":"mt-4","children":[["$","div",null,{"className":"flex justify-between text-[10px] uppercase tracking-widest text-slate-500","children":[["$","span",null,{"children":"Bearish"}],["$","span",null,{"children":"Bullish"}]]}],["$","div",null,{"className":"relative mt-1 h-2 rounded-full bg-ink-900/60","children":[["$","div",null,{"className":"absolute left-1/2 top-0 h-full w-px bg-slate-600"}],["$","div",null,{"className":"absolute top-0 h-full w-2 rounded-full bg-yellow-500","style":{"left":"calc(51% - 4px)"}}]]}]]}],["$","div",null,{"className":"mt-4 flex gap-4 text-xs","children":[["$","span",null,{"className":"text-emerald-400","children":["â–² ",1," bullish"]}],["$","span",null,{"className":"text-red-400","children":["â–¼ ",0," bearish"]}],["$","span",null,{"className":"text-slate-500","children":[45," neutral"]}]]}],["$","p",null,{"className":"mt-1 text-xs text-slate-500","children":["Based on ",46," social post","s"]}],["$","div",null,{"className":"mt-4 space-y-2","children":[["$","p",null,{"className":"text-xs uppercase tracking-widest text-slate-500","children":"Recent mentions"}],[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to Botanix"}]]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to Botanix company"}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to Botanix Ltd"}]]}]]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Botanix Q2 FY26 Investor Update Webinar Presentation"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"26 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Quarterly Report"}]]}],""]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Botanix Quarterly Activities Report and Appendix 4C Q2 FY26"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"26 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Quarterly Report"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"Botanix, a Commitments Test Entity on ASX, reports strong quarterly performance with significant growth in its botanical derivatives portfolio for the June to August period of FY2026."}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Botanix Webinar - 27 January - Registration Information"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"21 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"General"}]]}],""]}],["$","div","3",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Application for quotation of securities - BOT"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"19 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does BOT do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does BOT do?"}],["$","p",null,{"className":"text-slate-400","children":"Botanix Pharmaceuticals is a dermatology company that develops treatments for skin conditions. Its lead product, Sofdraâ„¢, is an FDA-approved topical gel for treating excessive underarm sweating (primary axillary hyperhidrosis), which it is preparing to launch in the United States."}]]}],["$","div","Is BOT a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is BOT a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"Investing in BOT is speculative and carries both high potential rewards and significant risks. The recent FDA approval for Sofdraâ„¢ is a major milestone, but the company's success now hinges on executing a successful commercial launch in the competitive US market. While the potential market is large, investors should consider the significant risks associated with product launches, competition, and future funding requirements."}]]}],["$","div","What drives BOT's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives BOT's share price?"}],["$","p",null,{"className":"text-slate-400","children":"BOT's share price is primarily driven by news related to its lead product, Sofdraâ„¢. Key catalysts include updates on the US commercial launch, initial sales figures, securing insurance reimbursement coverage, and manufacturing agreements. Progress in its earlier-stage development pipeline and any capital market activities also significantly influence its valuation."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","0.12"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-red-400","children":["-73.6","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$236M"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"24/01/1985"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L4",null,{"href":"/asx/CSL","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","180.50"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$87.9B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/PNV","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.92"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-20.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$687M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/1AD","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.00"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-33.0","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$13M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$6","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L4",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L8",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L4","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L4","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L4","/sectors",{"href":"/sectors","className":"transition hover:text-white","children":"Sectors"}],["$","$L4","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L4","/ipos",{"href":"/ipos","className":"transition hover:text-white","children":"IPOs"}],["$","$L4","/compare",{"href":"/compare","className":"transition hover:text-white","children":"Compare"}],["$","$L4","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 md:flex","children":[["$","$L9",null,{}],["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden","children":[["$","div",null,{"className":"flex-1","children":["$","$L9",null,{}]}],["$","$L4",null,{"href":"/screener","className":"shrink-0 text-xs text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L4",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/5bd3404007bffd2a.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$La"]]]]]
a:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"BOT share price, analysis & company profile - Botanix Pharmaceuticals Ltd | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest BOT share price overview, what Botanix Pharmaceuticals Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/BOT/"}],["$","meta","5",{"property":"og:title","content":"BOT share price, analysis & company profile - Botanix Pharmaceuticals Ltd"}],["$","meta","6",{"property":"og:description","content":"Latest BOT share price overview, what Botanix Pharmaceuticals Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/BOT/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"BOT share price, analysis & company profile - Botanix Pharmaceuticals Ltd"}],["$","meta","11",{"name":"twitter:description","content":"Latest BOT share price overview, what Botanix Pharmaceuticals Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
